Insider Selling: Simulations Plus, Inc. (NASDAQ:SLP) Director Sells 20,000 Shares of Stock

Simulations Plus, Inc. (NASDAQ:SLP) Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $27.66, for a total value of $553,200.00. Following the completion of the sale, the director now directly owns 3,462,584 shares in the company, valued at $95,775,073.44. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Simulations Plus Price Performance

Shares of SLP stock traded down $0.11 during midday trading on Tuesday, hitting $27.38. The company had a trading volume of 1,596 shares, compared to its average volume of 132,352. The company’s 50 day simple moving average is $32.09 and its 200 day simple moving average is $39.78. Simulations Plus, Inc. has a 52-week low of $27.22 and a 52-week high of $51.22. The stock has a market cap of $549.52 million, a price-to-earnings ratio of 56.10 and a beta of 0.71.

Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings results on Wednesday, October 23rd. The technology company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. Simulations Plus had a return on equity of 6.16% and a net margin of 14.15%. The firm had revenue of $18.70 million for the quarter, compared to the consensus estimate of $19.73 million. During the same period in the previous year, the business earned $0.18 earnings per share. The company’s revenue for the quarter was up 19.9% compared to the same quarter last year. Analysts anticipate that Simulations Plus, Inc. will post 1.11 EPS for the current year.

Institutional Trading of Simulations Plus

A number of institutional investors have recently modified their holdings of SLP. Public Employees Retirement System of Ohio acquired a new position in shares of Simulations Plus in the first quarter worth $1,082,000. Silvercrest Asset Management Group LLC acquired a new position in Simulations Plus in the first quarter valued at $4,717,000. Deerfield Management Company L.P. Series C purchased a new stake in Simulations Plus during the second quarter valued at about $811,000. Allspring Global Investments Holdings LLC purchased a new stake in Simulations Plus during the first quarter valued at about $70,000. Finally, Tributary Capital Management LLC grew its position in Simulations Plus by 54.7% during the third quarter. Tributary Capital Management LLC now owns 325,567 shares of the technology company’s stock valued at $10,425,000 after acquiring an additional 115,122 shares during the period. 78.08% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on SLP shares. William Blair reaffirmed an “outperform” rating on shares of Simulations Plus in a research report on Thursday, October 24th. KeyCorp assumed coverage on Simulations Plus in a research report on Monday, July 29th. They set an “overweight” rating and a $47.00 target price on the stock. BTIG Research cut their target price on Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. JMP Securities assumed coverage on Simulations Plus in a research report on Tuesday, July 16th. They set a “market perform” rating on the stock. Finally, StockNews.com lowered Simulations Plus from a “hold” rating to a “sell” rating in a research report on Monday. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $54.50.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.